1.Although this Pacritinib (HY-16379) is commonly used for oral administration, it is also suitable for intraperitoneal injection (i.p. injection). Please refer to the literature reports (PMID: 32929154).

2. Initially, it is necessary to establish the animal experimental dose (mg/kg). Subsequently, the concentration of the working solution can be calculated, followed by the determination of the concentration of the Pacritinib stock solution in DMSO. Provided the solubility is adequate, a vehicle comprising 10% DMSO and 90% of 20% SBE-β-CD in saline may be employed for intraperitoneal administration. However, if the mice are debilitated or have been subjected to previous experimental disease models, it is advisable to reduce the DMSO concentration to 2%.

The answer to this question comes from MedChemExpress Technical Support. [email protected]